Proteon Therapeutics Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Employees
-
17
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$42.5M
Proteon Therapeutics General Information
Description
Provider of transformative therapies intended for people with cancer and rare diseases with limited treatment options. The company's portfolio includes an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and also an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease, thereby addressing the needs of patients with the renal and vascular disease.
Contact Information
Website
www.proteontherapeutics.comCorporate Office
- 200 West Street
- Waltham, MA 02451
- United States
Corporate Office
- 200 West Street
- Waltham, MA 02451
- United States
Proteon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 09-Jan-2020 | $42.5M | Completed | Generating Revenue | ||
| 11. Secondary Transaction - Open Market | 26-Jun-2017 | Completed | Generating Revenue | |||
| 10. IPO | 22-Oct-2014 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series D) | 28-May-2014 | Completed | Generating Revenue | |||
| 8. Merger/Acquisition | 18-Mar-2014 | Cancelled | Generating Revenue | |||
| 7. Later Stage VC (Series C) | 19-Feb-2014 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 11-Aug-2011 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 28-May-2009 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 28-May-2009 | $23.9M | $59.4M | Completed | Generating Revenue | |
| 3. Early Stage VC (Series A1) | 06-Sep-2007 | $12M | $35.6M | Completed | Product Development |
Proteon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A1 | 10,909,091 | $0.001000 | $0.08 | $1.1 | $1.1 | 1x | $0.9 | 6.54% |
| Series A | 22,638,465 | $0.001000 | $0.07 | $1 | $1 | 1x | $0.84 | 13.27% |
Proteon Therapeutics Comparisons
Industry
Financing
Details
Proteon Therapeutics Competitors (57)
One of Proteon Therapeutics’s 57 competitors is Akebia Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Akebia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Pharmacosmos | Corporate Backed or Acquired | Holbaek, Denmark | ||||
| SanBio | Formerly VC-backed | Tokyo, Japan | ||||
| Resverlogix | Corporation | Calgary, Canada | ||||
| Syntara | Formerly VC-backed | Frenchs Forest, Australia |
Proteon Therapeutics Patents
Proteon Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11311503-B1 | Sterile aqueous choline salt compositions | Active | 29-Apr-2021 | ||
| US-20230024844-A1 | Sterile aqueous choline salt compositions | Active | 29-Apr-2021 | ||
| JP-2024518046-A | Sterile aqueous choline salt compositions | Pending | 29-Apr-2021 | ||
| EP-4329723-A1 | Sterile aqueous choline salt compositions | Pending | 29-Apr-2021 | ||
| CA-3214381-A1 | Sterile aqueous choline salt compositions | Pending | 29-Apr-2021 | A61K9/0019 |
Proteon Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Proteon Therapeutics Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abingworth | Venture Capital | Minority | ||
| BPEA Private Equity | PE/Buyout | Minority | ||
| Bessemer Venture Partners | Venture Capital | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Deutsche Bank | Investment Bank | Minority |
Proteon Therapeutics Acquisitions (1)
Proteon Therapeutics’s most recent deal was a Reverse Merger with Protara Therapeutics. The deal was made on 09-Jan-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Protara Therapeutics | 09-Jan-2020 | Reverse Merger | Drug Discovery |
Proteon Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Proteon Therapeutics FAQs
-
When was Proteon Therapeutics founded?
Proteon Therapeutics was founded in 2001.
-
Where is Proteon Therapeutics headquartered?
Proteon Therapeutics is headquartered in Waltham, MA.
-
What is the size of Proteon Therapeutics?
Proteon Therapeutics has 17 total employees.
-
What industry is Proteon Therapeutics in?
Proteon Therapeutics’s primary industry is Pharmaceuticals.
-
Is Proteon Therapeutics a private or public company?
Proteon Therapeutics is a Private company.
-
What is the current valuation of Proteon Therapeutics?
The current valuation of Proteon Therapeutics is .
-
What is Proteon Therapeutics’s current revenue?
The current revenue for Proteon Therapeutics is .
-
How much funding has Proteon Therapeutics raised over time?
Proteon Therapeutics has raised $185M.
-
Who are Proteon Therapeutics’s investors?
Abingworth, BPEA Private Equity, Bessemer Venture Partners, Deerfield Management, and Deutsche Bank are 5 of 16 investors who have invested in Proteon Therapeutics.
-
Who are Proteon Therapeutics’s competitors?
Akebia Therapeutics, Pharmacosmos, SanBio, Resverlogix, and Syntara are some of the 57 competitors of Proteon Therapeutics.
-
When was Proteon Therapeutics acquired?
Proteon Therapeutics was acquired on 09-Jan-2020.
-
Who acquired Proteon Therapeutics?
Proteon Therapeutics was acquired by Protara Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
